Molecular Study of *Staphylococcus Epidermidis* Strains Isolated from Clinical Specimens from Different parts of Rouhani Hospital (Babol, Iran)

Meysam Maghsoodlou¹,², Mehdi Rajabnia³, Abolfazl Davoodabadi², Soraya Khafri⁴, Parisa Sabbagh⁵, Hamed Ghasemtabar³, Omid Mohammadi² and Amirmorteza Ebrahimzadeh Namvar*²,³

¹Student Research Committee, Babol University of Medical Sciences, Babol, IR Iran
²Department of Microbiology, School of Medicine, Babol University of Medical Sciences, Babol, IR Iran
³Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, IR Iran
⁴Department of Biostatistics and epidemiology, Faculty of Medicine, Babol University of Medical Sciences, Babol, IR Iran
⁵Department of Laboratory Medicine, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, IR Iran

Received: December 11, 2018; Published: January 02, 2019

*Corresponding author: Amirmorteza Ebrahimzadeh Namvar, Department of Microbiology, Faculty of Medicine, Babol, IR Iran

Abstract

Introduction: *Staphylococcus epidermidis* is known as the most predominant member of coagulase negative staphylococci which can cause nosocomial infections especially in ICU and NICU wards.

Aim: The aim of this study was to investigate the molecular characterization of *S. epidermidis* strains obtained from the Rouhani Hospital in Babol, Iran.

Materials and Methods: In this descriptive study, a total of 60 *S. epidermidis* strains were collected. Thereafter, the antimicrobial susceptibility testing, the prevalence of *mecA* and *icaD* gene was evaluated. Finally the molecular pattern of isolates was determined by using RAPD-PCR technique.

Results: A total of 50 clinical strains and 10 environmental isolates were obtained from hospitalized patients from different specimens such as bloodstream, urine, catheter, body fluids and etc. by disc diffusion method the high rates of resistance were belonged to oxacillin (70.5%) and ciprofloxacin (63.9%). The prevalence of *mecA* and *icaD* genes was reported 85% and 41.6% respectively. 24 RAPD-Type was identified by using RAPD-PCR method which indicates the high genotypic diversity in the *S. epidermidis* isolates.

Conclusion: The high risk of transmission of infection between the wards and also the Rouhani Hospital staff should be taken seriously.

Keywords: *Staphylococcus Epidermidis*; Molecular Typing; ICU; Nosocomial Infections

Introduction

Staphylococci are known as a gram-positive, non-motile and non-spore forming cocci which are divided into two mains coagulase-negative and coagulase-positive staphylococci [1]. *Staphylococcus epidermidis* with the highest prevalence rate is recognized as the most significant member of the family of coagulase-negative staphylococci and plays an important role in nosocomial infections [2]. *S. epidermidis* is considered as the main contributor in medical equipment infections. In recent decades, due to the clinical importance and emergence of methicillin-resistant *S. epidermidis* strains, this organism has become a challenge in the treatment of patients [3]. Several virulence factors and resistance genes were identified in which the *mecA* and *ica* gene are the important one [4]. Many strains of *S. epidermidis* produce an N acetylglucosamine (PNAG) homopolymer, called PIA which is associated in biofilm formation [5].

PIA is the main element of the extracellular matrix that is produced by the *ica* gene. The *ica* gene products include *icaA*, *icaD*, *icaB* and *icaC* [2]. Identification of these virulence factors is essential in control and prevention of outbreak infections. One of the most effective techniques in this issue is using molecular typing methods. Due to *S. epidermidis* related infections various typing methods were described such as analysis of plasmid and Restriction enzymes, DNA hybridization, RAPD-PCR, SCCmec typing, PFGE
and MLST [2]. As mentioned methods Random Amplification of Polymorphic DNA (RAPD) is a type of modified PCR method in which short-term random sequences are able to attach in different locations of the genome and can produce a range of amplified PCR products [6,7]. The aim of this study was to investigate the molecular characterization of S. epidermidis strains obtained from the Rouhani Hospital in Babol, Iran.

Materials and Methods
Isolation and Identification

A total of 50 S. epidermidis strains were collected from bloodstream, urine, catheter, shunt, body fluids and wound infections from different wards including open heart surgery, orthopedics, neurology, infectious disease, ICU and NICU of Rouhani Hospital. In addition a total of 10 S. epidermidis strains were obtained from hospital staff for RAPD-PCR test. The isolates were referred to the laboratory of the Babol University of Medical Sciences for confirmation by microbiological test such as gram staining, catalase, coagulase, mannitol fermentation on mannitol salt agar media and sensitivity to polymyxin B and finally stored at -20 °C.

Table 1: Specific primers for amplification of mecA and icaD genes.

| Gene | Nucleotide sequences | Size (bp) | Reference |
|------|----------------------|-----------|-----------|
| mecA | F: 5’-AGTCTCTAGATCGGATG-3’<br>R: 5’-AAAATCGATGGTAAAGGTTGGC-3’ | 533 | [7]|
| icaD | F: 5’-GAACGCCGTTCATGTTG-3’<br>R: 5’-GGTGAACATGTGGCTAACC3’ | 483 | [8]|

RAPD Analysis

The DNA genomic was extracted by commercial kit (Yekta-Tajhiz, Iran) and RAPD-PCR assay was carried out according to procedure described previously by Burucoa [8,9]. PCR was performed in a final volume of 25µl containing 12.5µl Super MasterMix 2X, 1µl Primer (5’-CGG CAG CCA A-3’), 3µl DNA template and 7.5µl Sterile Deionized Water. PCR cycles was perform with initial denaturation temperature of 94°C for 5 minutes, then 30 cycles with a denaturation temperature of 94°C for 30 seconds, annealing temperature of 55°C for 30 seconds, and an extension temperature of 72°C for 40 seconds and a final extension cycle was performed at a temperature of 72°C for 5 minutes. The specific primers are shown in (Table 1).

Antimicrobial Susceptibility Testing

Antibiogram test was performed by disk diffusion method according to CLSI 2016 standards. In this test, Muller Hinton Agar (Merck - Germany) and antibiotic disks included Cefoxitin (30 µg), Oxacillin (1 µg), Gentamicin (10 µg), Erythromycin (15 µg), Clindamycin (2 µg), Ciprofloxacin (5 µg), Fusidic acid (10 µg), Levofloxacin (30 µg), Trimethoprim/Sulfamethoxazole (1.25/23.73 µg), Vancomycin (30 µg), and Linezolid (30 µg) (ROSCO - Denmark) was used.

PCR Amplification for mecA and icaD Genes

In order to perform PCR, the MasterMix was prepared in a final volume of 25µl, including: 12.5µl Super MasterMix 2X, 1µl of each primer (Forward & Reverse), 3µl DNA template and 7.5µl Sterile Deionized Water. PCR cycles was perform with initial denaturation temperature of 94°C for 5 minutes, then 30 cycles with a denaturation temperature of 94°C for 30 seconds, annealing temperature of 55°C for 30 seconds, and an extension temperature of 72°C for 40 seconds and a final extension cycle was performed at a temperature of 72°C for 5 minutes. The specific primers are shown in (Table 1).

Results

Table 2: S. epidermidis strains in details including isolation ward, RAPD-Type, mecA and icaD genes and resistance pattern.

| Strain | Ward | RAPD Type | mecA Gene | icaD Gene | Resistance pattern |
|--------|------|-----------|-----------|-----------|--------------------|
| 7      | ICU  | R-1       | Positive  | Negative  | OXA-FU-CLI-FOX     |
| 8      | ICU  | R-1       | Positive  | Negative  | E-GM-FOX-OXA-CLI-CIP-LEV     |
| 9      | NICU | R-1       | Positive  | Negative  | OXA-GM-CLI-E-CIP-FU-FOX     |
| 4      | CCU  | R-1       | Positive  | Negative  | LEV-CLI-CIP-OXA-GM-E-FOX     |
| 11     | Pulmonary | R-1     | Positive  | Positive  | E-FOX-OXA-CIP-GM-SXT-LEV-CLI |
| 15     | NICU | R-2       | Positive  | Positive  | OXA-FOX              |
| 16     | CCU  | R-2       | Positive  | Positive  | CLI-FOX              |
| 17     | ENT  | R-2       | Positive  | Negative  | OXA-FOX-GM-E-CLI-SXT   |
| 36     | NICU | R-3       | Positive  | Positive  | CIP-GM-E-FOX-OXA-LEV-CLI-FU |
| 12     | ICU  | R-4       | Positive  | Positive  | OXA-GM-CIP-FOX-E-FU-CLI-LEV |
| 13     | ICU  | R-4       | Positive  | Negative  | OXA-GM-CIP-FOX-E-FU-CLI-LEV |
| 14     | CCU  | R-4       | Positive  | Negative  | CIP-GM-E-FOX-OXA-SXT-CLI-FU |
| 28     | ICU  | R-4       | Positive  | Negative  | CIP-GM-E-FOX-OXA-SXT-CLI-FU |
|   | Setting     | Lab No | Sensitivity | Resistance | Antimicrobial Susceptibility Pattern |
|---|-------------|--------|-------------|------------|-------------------------------------|
| 1 | ENT         | R-21   | Negative    | Positive   | E                                   |
| 2 | ICU         | R-2     | Positive    | Negative   | OXA-GM-FOX-FOX-CLI-LEV-SXT-FOX-E    |
| 3 | ICU         | R-6    | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-LEV-SXT-FOX-E   |
| 4 | ICU         | R-7    | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-LEV-SXT-FOX-E   |
| 5 | ICU         | R-10   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-LEV-SXT-FOX-E   |
| 6 | ICU         | R-11   | Positive    | OXA-FOX-FOX-CLI-SXT-FOX-E            |
| 7 | ICU         | R-12   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 8 | ICU         | R-13   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 9 | ICU         | R-14   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 10| ICU         | R-15   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 11| ICU         | R-16   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 12| ICU         | R-17   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 13| ICU         | R-18   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 14| ICU         | R-19   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 15| ICU         | R-20   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 16| ICU         | R-21   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 17| ICU         | R-22   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 18| ICU         | R-23   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 19| ICU         | R-24   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 20| ICU         | R-25   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 21| ICU         | R-26   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 22| ICU         | R-27   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 23| ICU         | R-28   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 24| ICU         | R-29   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 25| ICU         | R-30   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 26| ICU         | R-31   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 27| ICU         | R-32   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 28| ICU         | R-33   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 29| ICU         | R-34   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 30| ICU         | R-35   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 31| ICU         | R-36   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 32| ICU         | R-37   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 33| ICU         | R-38   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 34| ICU         | R-39   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 35| ICU         | R-40   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 36| ICU         | R-41   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 37| ICU         | R-42   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 38| ICU         | R-43   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 39| ICU         | R-44   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 40| ICU         | R-45   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 41| ICU         | R-46   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 42| ICU         | R-47   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 43| ICU         | R-48   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 44| ICU         | R-49   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 45| ICU         | R-50   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 46| ICU         | R-51   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 47| ICU         | R-52   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 48| ICU         | R-53   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 49| ICU         | R-54   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 50| ICU         | R-55   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 51| ICU         | R-56   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 52| ICU         | R-57   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 53| ICU         | R-58   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 54| ICU         | R-59   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 55| ICU         | R-60   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 56| ICU         | R-61   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 57| ICU         | R-62   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 58| ICU         | R-63   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 59| ICU         | R-64   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |
| 60| ICU         | R-65   | Positive    | FOX-CIP    | OXA-FOX-CIP-FOX-CLI-SXT-FOX-E       |

**Cite this article:** Meysam M, Mehdi R, Abolfazl D, Soraya K, Amirmorteza E N et al., Molecular Study of Staphylococcus Epidermidis Strains Isolated from Clinical Specimens from Different parts of Rouhani Hospital (Babol, Iran). Biomed J Sci & Tech Res 12(4)-2019. BJSTR. MS.ID.002282. DOI: 10.26717/BJSTR.2019.12.002282.
A total of 60 *S. epidermidis* strains were collected from different wards of Rouhani Hospital. Due to our results the infectious diseases and ICU wards had the highest rate of specimens in comparison to other wards. 53% of isolates were belonged to female gender. By disc diffusion method no resistance was reported to vancomycin and linezolid, while the rate of resistance to oxacillin, gentamicin, cefoxitin, clindamycin, ciprofloxacin and erythromycin were 70.5%, 45.9%, 55.7%, 55.7%, 63.9% and 59% respectively. On the other hand, resistance to trimethoprim/sulfamethoxazole (39.4%), fusidic acid (25.4%) and levofloxacin (41%) was noticeable (Figure 1). The prevalence of *meca* and *icaD* genes was 85% and 41.6% respectively. There were no significant correlation between detected genes and gender (P-value > 0.05). In addition, twenty-four different RAPD-Types were analysis by 80% similarity cut-off point which indicates the high genotypic diversity in our isolates (Figure 2). Table 2 is shown the complete details of all studied isolates.

**Discussion**

According to the results, the presence of *meca* and *icaD* genes among *S. epidermidis* strains obtained from Rouhani Hospital in Babol was 85% and 41.6%, respectively. The frequency of these genes among similar studies is reported differently. In a study conducted by Najar-Peerayeh et al. The presence of the *meca* gene was 92.2% [11]. In the study of Pourmand et al., the frequency of *meca* gene was reported 95%, which is higher than of all conducted studies in Iran. Also, resistance to clindamycin and erythromycin in this study was 77% and 79%, respectively which is higher than our study [12]. Moreover, in Pishva et al. research in Al-Zahra Hospital in Isfahan, 75.3% of *S. epidermidis* strains harbored *meca* gene [13]. In a study by Soroush et al., on 80 *S. epidermidis* strains which was collected from children, 41% had *icaD* gene. In this study 90% of isolates were found multi-drug resistance, in which the rate of resistance to co-trimoxazole was reported 91.2%. On the other hand, no resistance was observed to linezolid and vancomycin [14].

Moreover, the RAPD-PCR results revealed that RAPD-Type 1 with 5 member followed by RAPD-Type 4, 7, 12 and 18 with four member were the main clusters in current study in comparison
to RAPD-Type 3, 5, 11, 13 and 22. These results indicated that the variety of *S. epidermidis* strains in different wards of the Rouhani Hospital in Babol was high, consequently, due to the wide range of pathogenic factors, *S. epidermidis* related infections is expected in different wards of the hospital. According to (Table 2), the RAPD-PCR method showed that a number of RAPD-Types had the same genotypic profiles and also the same antimicrobial resistance patterns such as RAPD-Type 1, 4, 7, etc. while, the isolation wards were different. There is a significant genetic relationship between the member of some clusters for instance RAPD-Type 4. However, a number of RAPD-Types (9, 12, 16, 17, 18 and 20) illustrated that there was coloration between clinical and environmental isolates. Due to our results, the bacterial infection between various wards and also staff hands and patients is a major concern. Although much progress has been made in molecular typing and more precise methods have been developed, such as PFGE and MLST, but RAPD-PCR has maintained its importance as a reliable, cost-effective and user-friendly method. We used RAPD-PCR in this study to find the phylogenetic relationship between *S. epidermidis* obtained from the Rouhani Hospital in Babol.

**Funding/SUPPORT**

This study was funded by the research committee of Babol University of Medical Sciences (Grant no. 3479).

**References**

1. Gerald Mandell JB, Raphael Dolin (2009) Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Elsevier.
2. Namvar AE, Bastararah S, Abbasi N, Ghazaleh Sheikh Ghebi, Sara Fatadabakhtian, et al. (2014) Clinical characteristics of *Staphylococcus epidermidis*: a systematic review. GMS Hgy Infect Control 9(3): Doi:22.
3. Otto M (2009) *Staphylococcus epidermidis*: the “accidental” pathogen. Nat REV Microbiol 7(8): 555-567.
4. Iorio NL, Azevedo MB, Frazao VH, Barcellos AG, Barros EM, Pereira EM, et al. (2011) Methicillin-resistant *Staphylococcus epidermidis* carrying biofilm formation genes: detection of clinical isolates by multiplex PCR. Int Microbiol 14(1): 13-17.
5. Conrady DG, Brescia CC, Horii D, Weiss AA, Hassett DJ, et al. (2008) A zinc-dependent adhesion module is responsible for intercellular adhesion in staphylococcal biofilms. Proc Natl Acad Sci U S A 105(49): 19456-19461.
6. Bardakci F. Random amplified polymorphic DNA (RAPD) Markers. Turk J Biol 25: 185-196.
7. Merlino J, Watson J, Rose B, Beard-Pegler M, Gottlieb T, et al. (2002) Detection and expression of methicillin/oxacillin resistance in multidrug-resistant and non-multidrug-resistant *Staphylococcus aureus* in Central Sydney, Australia. J Antimicrob Chemother 49(5): 793-801.
8. Namvar AE, Asghari B, Ezatifar F, Azizi G, Lari AR (2013) Detection of the intercellular adhesion gene cluster (ica) in clinical *Staphylococcus aureus* isolates. GMS Hgy InfectControl 8(1): Doc:03.
9. Burucoa C, Lhomme V, Fauchere JL (1999) Performance criteria of DNA fingerprinting methods for typing of *Helicobacter pylori* isolates: experimental results and meta-analysis. J Clin Microbiol 37(12): 4071-4080.
10. Mobasherizadeh S, Shojaei H, Havaei SA, Kamyar Mostafavizadeh, Fazolah Davoodabadi, et al. (2016) Application of the Random Amplified Polymorphic DNA (RAPD) Fingerprinting to Analyze Genetic Variation in Community-Associated-Methicillin Resistant *Staphylococcus aureus* (CA-MRSA) Isolates in Iran. Glob J Health Sci 8(6): 185-191.
11. Najar Peerayeh S, Jazayeri Moghadas A, Behmanesh M (2014) Antibiotic Susceptibility and mecA Frequency in *Staphylococcus epidermidis*, Isolated from Intensive Care Unit Patients. Jundishapur J Microbiol 7(8): e1188.
12. Pourmand MR, Abdossamadi Z, Salari MH, Hosseini M (2011) Slime layer formation and the prevalence of mecA and aap genes in *Staphylococcus epidermidis* isolates. Infect Dev Ctries 5(1): 34-40.
13. Pishva E, Havaei SA, Arslani F, Narimani T, Azimian A, et al. (2013) Detection of methicillin-resistance gene in *Staphylococcus epidermidis* strains isolated from patients in Al-Zahra Hospital using polymerase chain reaction and minimum inhibitory concentration methods. Adv Biomed Res 6(2): 23.
14. Soroush S, Jabalameli F, Taherikalani M, Amirmozafari N, Fooladi AA, et al. (2016) Investigation of biofilm formation ability, antimicrobial resistance and the prevalence of mecA and aap genes in *Staphylococcus aureus*, isolated from Central Sydney, Australia. J Antimicrob Chemother 71(12): 3916-3922.
15. J Biol 25(49): 19456-19461.
16. Bardakci F. Random amplified polymorphic DNA (RAPD) Markers. Turk J Biol 25: 185-196.
17. Merlino J, Watson J, Rose B, Beard-Pegler M, Gottlieb T, et al. (2002) Detection and expression of methicillin/oxacillin resistance in multidrug-resistant and non-multidrug-resistant *Staphylococcus aureus* in Central Sydney, Australia. J Antimicrob Chemother 49(5): 793-801.
18. Namvar AE, Asghari B, Ezatifar F, Azizi G, Lari AR (2013) Detection of the intercellular adhesion gene cluster (ica) in clinical *Staphylococcus aureus* isolates. GMS Hgy InfectControl 8(1): Doc:03.
19. Burucoa C, Lhomme V, Fauchere JL (1999) Performance criteria of DNA fingerprinting methods for typing of *Helicobacter pylori* isolates: experimental results and meta-analysis. J Clin Microbiol 37(12): 4071-4080.
20. Mobasherizadeh S, Shojaei H, Havaei SA, Kamyar Mostafavizadeh, Fazolah Davoodabadi, et al. (2016) Application of the Random Amplified Polymorphic DNA (RAPD) Fingerprinting to Analyze Genetic Variation in Community-Associated-Methicillin Resistant *Staphylococcus aureus* (CA-MRSA) Isolates in Iran. Glob J Health Sci 8(6): 185-191.
21. Najar Peerayeh S, Jazayeri Moghadas A, Behmanesh M (2014) Antibiotic Susceptibility and mecA Frequency in *Staphylococcus epidermidis*, Isolated from Intensive Care Unit Patients. Jundishapur J Microbiol 7(8): e1188.
22. Pourmand MR, Abdossamadi Z, Salari MH, Hosseini M (2011) Slime layer formation and the prevalence of mecA and aap genes in *Staphylococcus epidermidis* isolates. Infect Dev Ctries 5(1): 34-40.
23. Pishva E, Havaei SA, Arslani F, Narimani T, Azimian A, et al. (2013) Detection of methicillin-resistance gene in *Staphylococcus epidermidis* strains isolated from patients in Al-Zahra Hospital using polymerase chain reaction and minimum inhibitory concentration methods. Adv Biomed Res 6(2): 23.
24. Soroush S, Jabalameli F, Taherikalani M, Amirmozafari N, Fooladi AA, et al. (2016) Investigation of biofilm formation ability, antimicrobial resistance and the prevalence of mecA and aap genes in *Staphylococcus aureus*, isolated from Central Sydney, Australia. J Antimicrob Chemother 71(12): 3916-3922.